BrainStorm Cell Therapeutics reached an alignment with the FDA on key aspects of a planned Phase 3 trial of its NurOwn cell therapy for ALS.
BrainStorm, FDA align on important aspects of upcoming NurOwn trial – ALS News Today
About the Author:
BrainStorm Cell Therapeutics reached an alignment with the FDA on key aspects of a planned Phase 3 trial of its NurOwn cell therapy for ALS.
Leave A Comment